someone explain 503B to me like I have not read a paper in years
Question in the title, detail here: someone explain 503B to me like I have not read a paper in years.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.
If somebody has the same thing measured a different way, post it next to mine and we will see whether they agree.
best — the order this archive was captured in
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
Asked which facility and got a name straight away. Looked it up, found the registration, felt considerably better about the whole thing.
do not assume the concentration matches the branded product
That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.
That is not what patient-specific means.
ruben_cabrera is right about the concentration trap. It breaks arithmetic that has been reliable for months.
Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.
Asked for the beyond-use date basis and got a real answer with a stability reference attached.
This is the distinction the whole board runs on. Everything else follows from it.
a telehealth intake that asks nothing has told you what it is
a 503B has to register and report, so there is a paper trail to ask for
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
Reminder that nothing here is medical advice and this board cannot tell you which arrangement to choose.
What is the beyond-use date and what is it based on?
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
Did they name the facility?
Did they name the facility?
Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.
the pharmacy and the prescriber are two separate questions
Who is the prescriber, and are they the same organisation as the pharmacy?
What concentration is on the label, and does it match what you were expecting?
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
What concentration is on the label, and does it match what you were expecting?
Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.
- 1Salt form matters for mass: a preparation specified as one salt and dosed as…10 comments in this branch · started by u/rania_diallo